| 001 | 289500 | ||
| 005 | 20250512101328.0 | ||
| 024 | 7 | _ | |a 10.1007/s11060-024-04672-9 |2 doi |
| 024 | 7 | _ | |a pmid:38630384 |2 pmid |
| 024 | 7 | _ | |a 0167-594X |2 ISSN |
| 024 | 7 | _ | |a 1573-7373 |2 ISSN |
| 024 | 7 | _ | |a altmetric:162595711 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00822 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kocher, Daniela |0 P:(DE-He78)4679059a19b1f3cd341bd27d0ddb7c45 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines. |
| 260 | _ | _ | |a Dordrecht [u.a.] |c 2024 |b Springer Science + Business Media B.V |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1717508885_15355 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:B310#LA:B310# / 2024 Jun;168(2):317-332 |
| 520 | _ | _ | |a Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, rapid tumor regrowth, also referred to as rebound growth, may occur once treatment is stopped, constituting a significant clinical challenge.Four patient-derived pediatric glioma models were investigated to model rebound growth in vitro based on viable cell counts in response to MAPKi treatment and withdrawal. A multi-omics dataset (RNA sequencing and LC-MS/MS based phospho-/proteomics) was generated to investigate possible rebound-driving mechanisms. Following in vitro validation, putative rebound-driving mechanisms were validated in vivo using the BT-40 orthotopic xenograft model.Of the tested models, only a BRAFV600E-driven model (BT-40, with additional CDKN2A/Bdel) showed rebound growth upon MAPKi withdrawal. Using this model, we identified a rapid reactivation of the MAPK pathway upon MAPKi withdrawal in vitro, also confirmed in vivo. Furthermore, transient overactivation of key MAPK molecules at transcriptional (e.g. FOS) and phosphorylation (e.g. pMEK) levels, was observed in vitro. Additionally, we detected increased expression and secretion of cytokines (CCL2, CX3CL1, CXCL10 and CCL7) upon MAPKi treatment, maintained during early withdrawal. While increased cytokine expression did not have tumor cell intrinsic effects, presence of these cytokines in conditioned media led to increased attraction of microglia cells in vitro.Taken together, these data indicate rapid MAPK reactivation upon MAPKi withdrawal as a tumor cell intrinsic rebound-driving mechanism. Furthermore, increased secretion of microglia-recruiting cytokines may play a role in treatment response and rebound growth upon withdrawal, warranting further evaluation. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Cytokines |2 Other |
| 650 | _ | 7 | |a MAPK inhibitor |2 Other |
| 650 | _ | 7 | |a Pediatric low-grade glioma |2 Other |
| 650 | _ | 7 | |a Rebound growth |2 Other |
| 650 | _ | 7 | |a Treatment withdrawal |2 Other |
| 650 | _ | 7 | |a Tumor microenvironment |2 Other |
| 700 | 1 | _ | |a Cao, Lei |b 1 |
| 700 | 1 | _ | |a Guiho, Romain |b 2 |
| 700 | 1 | _ | |a Langhammer, Melanie |b 3 |
| 700 | 1 | _ | |a Lai, Yun-Lu |0 P:(DE-He78)b275d03e2b584bd4ed3029111aacd4a2 |b 4 |u dkfz |
| 700 | 1 | _ | |a Becker, Pauline |0 P:(DE-He78)c52829a04be6e20f457ba9454e37ab1f |b 5 |u dkfz |
| 700 | 1 | _ | |a Hamdi, Hiba |b 6 |
| 700 | 1 | _ | |a Friedel, Dennis |0 P:(DE-He78)263d95a5b6ba4abce7abee7185b9630e |b 7 |u dkfz |
| 700 | 1 | _ | |a Selt, Florian |0 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e |b 8 |u dkfz |
| 700 | 1 | _ | |a Vonhören, David |0 P:(DE-He78)c0872917a9023422a66a7e1c8080446b |b 9 |u dkfz |
| 700 | 1 | _ | |a Zaman, Julia |0 P:(DE-He78)786f582fd4178a697bb48213edd8aad4 |b 10 |u dkfz |
| 700 | 1 | _ | |a Valinciute, Gintvile |0 P:(DE-He78)40aa4331020bebaf3e1801700d2d3267 |b 11 |
| 700 | 1 | _ | |a Herter, Sonja |0 P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd |b 12 |u dkfz |
| 700 | 1 | _ | |a Picard, Daniel |0 P:(DE-He78)2d0b899984e41ffa8cb15d799d32afd1 |b 13 |u dkfz |
| 700 | 1 | _ | |a Rettenmeier, Johanna |0 P:(DE-He78)9eebe1af0e32ef6e4655e6ba195ef0ad |b 14 |u dkfz |
| 700 | 1 | _ | |a Maass, Kendra K |0 P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7 |b 15 |u dkfz |
| 700 | 1 | _ | |a Pajtler, Kristian W |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 16 |u dkfz |
| 700 | 1 | _ | |a Remke, Marc |b 17 |
| 700 | 1 | _ | |a von Deimling, Andreas |0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |b 18 |u dkfz |
| 700 | 1 | _ | |a Pusch, Stefan |0 P:(DE-He78)f2efee17b6ca2f790176a2c036912536 |b 19 |u dkfz |
| 700 | 1 | _ | |a Pfister, Stefan M |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 20 |u dkfz |
| 700 | 1 | _ | |a Oehme, Ina |0 P:(DE-He78)908367a659dea9e28dac34592b3c46e5 |b 21 |u dkfz |
| 700 | 1 | _ | |a Jones, David T W |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 22 |u dkfz |
| 700 | 1 | _ | |a Halbach, Sebastian |0 P:(DE-HGF)0 |b 23 |
| 700 | 1 | _ | |a Brummer, Tilman |0 P:(DE-He78)492a2f9f2a95bcb0609e37d1ce1e13a9 |b 24 |u dkfz |
| 700 | 1 | _ | |a Martinez-Barbera, Juan Pedro |b 25 |
| 700 | 1 | _ | |a Witt, Olaf |0 P:(DE-He78)143af26de9d57bf624771616318aaf7c |b 26 |u dkfz |
| 700 | 1 | _ | |a Milde, Till |0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f |b 27 |u dkfz |
| 700 | 1 | _ | |a Sigaud, Romain |0 P:(DE-He78)a5e60710c7515b3e1de74ced6928a9dd |b 28 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1007/s11060-024-04672-9 |0 PERI:(DE-600)2007293-4 |n 2 |p 317-332 |t Journal of neuro-oncology |v 168 |y 2024 |x 0167-594X |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289500/files/s11060-024-04672-9.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289500/files/s11060-024-04672-9.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:289500 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)4679059a19b1f3cd341bd27d0ddb7c45 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)b275d03e2b584bd4ed3029111aacd4a2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)c52829a04be6e20f457ba9454e37ab1f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)263d95a5b6ba4abce7abee7185b9630e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)c0872917a9023422a66a7e1c8080446b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)786f582fd4178a697bb48213edd8aad4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)40aa4331020bebaf3e1801700d2d3267 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)2d0b899984e41ffa8cb15d799d32afd1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)9eebe1af0e32ef6e4655e6ba195ef0ad |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)f2efee17b6ca2f790176a2c036912536 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)908367a659dea9e28dac34592b3c46e5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 23 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)492a2f9f2a95bcb0609e37d1ce1e13a9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)143af26de9d57bf624771616318aaf7c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)a5e60710c7515b3e1de74ced6928a9dd |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-08-20 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2023-08-20 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2023-08-20 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEURO-ONCOL : 2022 |d 2023-08-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-20 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-20 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-20 |
| 920 | 2 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B300-20160331 |k B300 |l KKE Neuropathologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pädiatrische Gliomforschung |x 4 |
| 920 | 1 | _ | |0 I:(DE-He78)FR01-20160331 |k FR01 |l DKTK Koordinierungsstelle Freiburg |x 5 |
| 920 | 0 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B310-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B300-20160331 |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B360-20160331 |
| 980 | _ | _ | |a I:(DE-He78)FR01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::